OBJECTIVES: To examine rates of smoking and tobacco treatment utilization by insurance coverage status (Medicaid, commercial, exchange) among newly enrolled patients in the post Affordable Care Act (ACA) era. METHODS: We examined new members who enrolled in Kaiser Permanente Northern California through Medicaid, the California exchange, or nonexchange commercial plans (N=122,298) in the first 6 months of 2014 following ACA implementation. We compared these groups on smoking prevalence and tested whether smokers in each group differed on sociodemographic characteristics and in their utilization of tobacco treatment (pharmacotherapy and counseling) in 2014. RESULTS: Smoking prevalence was higher among Medicaid (22%) than exchange (13%) or commercial (12%) patients (P<0.0001). Controlling for key sociodemographic and clinical characteristics, Medicaid (odds ratio, 1.49; 95% confidence interval, 1.29-1.73) smokers had greater odds of tobacco treatment use than commercial smokers. Other groups at risk for underuse included men, younger patients, Asians, and Latinos. CONCLUSIONS: In this cohort of newly enrolled patients after ACA implementation, Medicaid patients were more likely to be smokers compared with exchange and commercial patients, but they were also more likely to use tobacco treatment. Low tobacco treatment use among exchange and commercial plan smokers, as well as younger men, Asians and Latinos poses a significant obstacle to improving public health and additional targeted outreach strategies may be needed to engage these patients with available health services.
OBJECTIVES: To examine rates of smoking and tobacco treatment utilization by insurance coverage status (Medicaid, commercial, exchange) among newly enrolled patients in the post Affordable Care Act (ACA) era. METHODS: We examined new members who enrolled in Kaiser Permanente Northern California through Medicaid, the California exchange, or nonexchange commercial plans (N=122,298) in the first 6 months of 2014 following ACA implementation. We compared these groups on smoking prevalence and tested whether smokers in each group differed on sociodemographic characteristics and in their utilization of tobacco treatment (pharmacotherapy and counseling) in 2014. RESULTS: Smoking prevalence was higher among Medicaid (22%) than exchange (13%) or commercial (12%) patients (P<0.0001). Controlling for key sociodemographic and clinical characteristics, Medicaid (odds ratio, 1.49; 95% confidence interval, 1.29-1.73) smokers had greater odds of tobacco treatment use than commercial smokers. Other groups at risk for underuse included men, younger patients, Asians, and Latinos. CONCLUSIONS: In this cohort of newly enrolled patients after ACA implementation, Medicaid patients were more likely to be smokers compared with exchange and commercial patients, but they were also more likely to use tobacco treatment. Low tobacco treatment use among exchange and commercial plan smokers, as well as younger men, Asians and Latinos poses a significant obstacle to improving public health and additional targeted outreach strategies may be needed to engage these patients with available health services.
Authors: Arnold H Levinson; Eliseo J Pérez-Stable; Paula Espinoza; Estevan T Flores; Tim E Byers Journal: Am J Prev Med Date: 2004-02 Impact factor: 5.043
Authors: Arnold H Levinson; Evelinn A Borrayo; Paula Espinoza; Estevan T Flores; Eliseo J Pérez-Stable Journal: Am J Prev Med Date: 2006-06-05 Impact factor: 5.043
Authors: Vilma E Cokkinides; Michael T Halpern; Elizabeth M Barbeau; Elizabeth Ward; Michael J Thun Journal: Am J Prev Med Date: 2008-05 Impact factor: 5.043
Authors: Kelly C Young-Wolff; Andrea H Kline-Simon; Smita Das; Don J Mordecai; Chris Miller-Rosales; Constance Weisner Journal: Psychiatr Serv Date: 2016-04-15 Impact factor: 3.084
Authors: Kelly C Young-Wolff; Sara R Adams; Daniella Klebaner; Alyce S Adams; Cynthia I Campbell; Derek D Satre; Judith J Prochaska Journal: Med Care Date: 2018-11 Impact factor: 2.983
Authors: Steffani R Bailey; Miguel Marino; David Ezekiel-Herrera; Teresa Schmidt; Heather Angier; Megan J Hoopes; Jennifer E DeVoe; John Heintzman; Nathalie Huguet Journal: Nicotine Tob Res Date: 2020-05-26 Impact factor: 4.244
Authors: Su Fen Lubitz; Alex Flitter; E Paul Wileyto; Douglas Ziedonis; Nathaniel Stevens; Frank Leone; David Mandell; John Kimberly; Rinad Beidas; Robert A Schnoll Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Vanessa A Palzes; Andrea H Kline-Simon; Derek D Satre; Stacy Sterling; Constance Weisner; Felicia W Chi Journal: J Stud Alcohol Drugs Date: 2020-07 Impact factor: 2.582
Authors: Andy S L Tan; Kelly C Young-Wolff; Lisa Carter-Harris; Ramzi G Salloum; Smita C Banerjee Journal: Nicotine Tob Res Date: 2018-11-15 Impact factor: 4.244
Authors: Ramin Mojtabai; Kira E Riehm; Joanna E Cohen; G Caleb Alexander; Jon S Vernick; Johannes Thrul Journal: Prev Med Date: 2020-04-22 Impact factor: 4.018
Authors: Matthew E Hirschtritt; Vanessa A Palzes; Andrea H Kline-Simon; Kurt Kroenke; Cynthia I Campbell; Stacy A Sterling Journal: Am J Manag Care Date: 2019-12-01 Impact factor: 2.229